Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma

Bristol Myers Squibb and partner 2Seventy bio see potential for earlier use of their multiple myeloma treatment Abecma after reporting clinical trial results that showed the CAR-T cell therapy outperformed standard drug regimens.